SCHEMBL2884299

SCHEMBL2884299

CC(C)(C)S(=O)(=O)N[C@H]1CC[C@H](c2nc3ccc(C(F)(F)F)cc3[nH]2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 5/20 0.48
TRPV1 Q8NER1 1/20 0.46
KCNH2 Q12809 3/20 0.46
ADRA1A P35348 2/20 0.46
ALDH1A1 P00352 1/20 0.45
LMNA P02545 1/20 0.45
MAPT P10636 1/20 0.45
HTT P42858 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
IDH2 P48735 1/20 0.44
IDO1 P14902 1/20 0.43
DGAT1 O75907 2/20 0.42
SCN10A Q9Y5Y9 1/20 0.42
PDE2A O00408 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
SOAT1 P35610 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2884297 0.92 NPY5R (0.46) NPY5RTRPV1KCNH2ADRA1AALDH1A1
SCHEMBL2884294 0.92 NPY5R (0.46) NPY5RTRPV1KCNH2ADRA1AALDH1A1
SCHEMBL2884131 0.82 NPY5R (0.49) NPY5RTRPV1ALDH1A1LMNAMAPT
SCHEMBL8528320 0.78 NPY5R (0.45) NPY5RKCNH2ADRA1AIDH2DGAT1
SCHEMBL2884373 0.77 NPY5R (0.54) NPY5RTRPV1ALDH1A1LMNAMAPT
SCHEMBL2884128 0.76 HTR2B (0.47) NPY5RPDE2A
SCHEMBL2884125 0.76 HTR2B (0.47) NPY5RPDE2A
Hydrochloric Acid SCHEMBL3706846 0.74 NPY5R (0.54) NPY5RTRPV1KCNH2ADRA1AMAPT
SCHEMBL91031 0.74 KDM1A (0.49) NPY5RKCNH2
SCHEMBL71894 0.72 KIT (0.40) NPY5R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7691860-B2 Sulfonamide derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-04-06 US claimed
US-20080161326-A1 Novel Sulfone Amide Amide Derivatives MSD K.K. (JP) 2008-07-03 US claimed
EP-1719765-A1 NOVEL SULFONE AMIDE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-08 EP claimed
US-7691860-B2 Sulfonamide derivatives BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-04-06 US disclosed
US-20080161326-A1 Novel Sulfone Amide Amide Derivatives MSD K.K. (JP) 2008-07-03 US disclosed
EP-1719765-A1 NOVEL SULFONE AMIDE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161326-A1 Novel Sulfone Amide Amide Derivatives NPY1R, NPY2R, NPY5R NPY5R 3/4885TRPV1 1261/4885KCNH2 2387/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.